marked.bio

neoepitope cancer vaccine ยท vaccine

OSE2101

1 active trials across 2 of our biomarkers, targeting neoepitopes. Not approved for any biomarker on marked.bio yet.

Also known as Tedopi.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 1 Phase 3
KRAS G12C 1 1 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of OSE2101.

  1. OSE Immunotherapeutics 1

Trials

1 of 1 trials shown

  1. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    Recruiting Phase 3 OSE Immunotherapeutics Started 2024Primary completion 2027-12 NCT06472245

    OSE2101docetaxel

    KRAS G12C and BRAF mutations) after Sponsor' agreement.

    KRAS G12CBRAF V600EPatients With Non-Small Cell Lung Cancer